Decoding YOD1: Insights into tumour regulation and translational opportunities

• Published in: Biochemical pharmacology Vol. 236; p. 116889
• Main Author: Zhi-Xiong, Chong
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.06.2025
• Subjects: Animals; Biomarker; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Deubiquitinase; Gene Expression Regulation, Neoplastic - physiology; Humans; Neoplasms - genetics; Neoplasms - metabolism; Therapeutic target; Translational Research, Biomedical - methods; Tumour-regulation; YOD1; IHC; PTEN; HR; CDK; PRDM1; RNF; ncRNA; TAZ; Therapeutic target; CTGF; APML; nTPM; YY1; OTU; PEDF; TNM; PSMD7; Deubiquitinase; LATS; ANKRD1; mTOR; qPCR; TIMP1; TNBC; RFS; AA; AML; GTEx; RARα; CAF; YOD1; MAPK; DUBRI; EMT; ERAD; pLDDT; TSS; HNSCC; HPA; NF; ADAM9; AMPK; Tumour-regulation; BPH; HspBP1; STAMBP; FC; ERK; RAI14; OTUB2; ceRNA; Biomarker; VCP; HLF; lncRNA; MINDY2; BiP; PTM; XIAP; YAP; mRNA; miRNA; TGF-β; SMAD; GH; HIF; JUP; KO; OS; CI; TUG; IGF; AKT; MARK; PML; ITCH; MAVS; REST; USP; DEX; NEDD4; NTNBC; TP; XAF1; TRIM33; TS

[Display omitted] YOD1 deubiquitinase is a 38 kDa protein that belongs to the ovarian tumour protease (OTU) family, and its dysregulation can precipitate cancer development. Still, an up-to-date review article that can summarize its detailed tumour-regulatory function and translational potentials in...